The clinical implications of sunitinib-induced hypothyroidism: A prospective evaluation

British Journal of Cancer

Volumn 99, Issue 3, 2008, Pages 448-454

  Wolter, P ^a   Stefan, C ^a   Decallonne, B ^a   Dumez, H ^a   Bex, M ^a   Carmeliet, P ^b,c   Schoffski P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Cardiac Unit   (Belgium)

Author keywords

Gastrointestinal stromal tumour; Hypothyroidism; Prospective study; Renal cell carcinoma; Sunitinib

Indexed keywords

BEVACIZUMAB; CYTOKINE; IMATINIB; RECOMBINANT INTERLEUKIN 2; SUNITINIB; THYROID ANTIBODY; THYROTROPIN;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; INCIDENCE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; THYROID DISEASE; THYROID FUNCTION; THYROID FUNCTION TEST;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; THYROID FUNCTION TESTS;

EID: 48349122489     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604497     Document Type: Article

References (33)

1. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM (2006) Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290: H547-H559
2. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, De Primo SE, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810-1816
3. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884-896
4. de Groot JW, Links TP, van der Graaf WT (2006) Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 17: 1719-1720
5. Demers LM (2004) Thyroid disease: pathophysiology and diagnosis. Clin Lab Med 24: 19-28
6. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338
7. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145: 660-664
8. Ellerhorst JA, Cooksley CD, Broemeling L, Johnson MM, Grimm EA (2003) High prevalence of hypothyroidism among patients with cutaneous melanoma. Oncol Rep 10: 1317-1320
9. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35
10. Garfield DH, Hercbergs A, Davis PJ (2007) Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 975-976
11. Gartner W, Weissel M (2004) Do iodine-containing contrast media induce clinically relevant changes in thyroid function parameters of euthyroid patients within the first week? Thyroid 14: 521-524
12. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13: 1367-1373
13. Jiskra J, Limanova Z, Barkmanova J, Smutek D, Friedmannova Z (2004) Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Physiol Res 53: 693-702
14. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576
15. Laurberg P, Andersen S, Bulow PI, Carle A (2005) Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment. Drugs Aging 22: 23-38
16. Lazarus JH (2007) Aspects of treatment of subclinical hypothyroidism. Thyroid 17: 313-316
17. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casari P, Beck-Peccoz P, Fugazzola L (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92: 3531-3534
18. Martorella AJ, Omry G, Hann LE, Motzer RJ, Robbins RJ (2006) Receptor kinase (RTK) inhibitor SU11248 may cause hypothyroidism in a select group of patients with metastatic renal cell carcinoma (RCC). 88th Annual Meeting of the Endocrine Society, Boston, MA, USA
19. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, Deprimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24
20. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 81-83
21. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R (2007) Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12: 107-113
22. Roskoski Jr R (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356: 323-328
23. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Halter DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ (2007) Phase II trial of sunitinib in patients with metastatic with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 20: 4793-4799
24. Schöffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van PH (2006a) Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17: 1185-1196
25. Schöffski P, Wolter P, Himpe A, Dychter SS, Abraham S, Baum C, Peren H, Wildiers H, Bex M, Dumez H (2006b) Sunitinib-related thyroid dysfunction: a single center retrospective and prospective evaluation. J Clin Oncol 24(18S): 3092
26. Shah M, Orengo IF, Rosen T (2006) High prevalence of hypothyroidism in male patients with cutaneous melanoma. Dermatol Online J 12: 1
27. Shaheen PE, Tamaskar IR, Salas RN, Rini BI, Garcia J, Wood L, Dreicer R, Bukowski RM (2006) Thyroid function tests abnormalities in patients treated with metastatic renal cell carcinoma treated with sunitinib. J Clin Oncol 24(18S): 4605
28. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650-656
29. Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH (1990) American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 263: 1529-1532
30. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291: 228-238
31. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI (2008) Thyroid dysfunction test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19: 265-268
32. Wolter P, Dumez H, Schoffski P (2007) Sunitinib and hypothyroidism. N Engl J Med 356: 1580-1581
33. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17: 351-355